- Home
- SAFE vs SPRY Comparison
SAFE vs SPRY Comparison
Compare SAFE & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SAFE | SPRY |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.4M | 1.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SAFE | SPRY |
|---|---|---|
| Price | $14.12 | $10.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $18.80 | ★ $35.00 |
| AVG Volume (30 Days) | 429.5K | ★ 1.7M |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $398,968,000.00 | $142,772,000.00 |
| Revenue This Year | $0.88 | N/A |
| Revenue Next Year | $3.64 | $123.33 |
| P/E Ratio | $9.54 | ★ N/A |
| Revenue Growth | 2.96 | ★ 5459.66 |
| 52 Week Low | $12.76 | $6.66 |
| 52 Week High | $19.53 | $18.90 |
Technical Indicators
Market Signals| Indicator | SAFE | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 44.68 |
| Support Level | $14.51 | $10.02 |
| Resistance Level | $15.31 | $11.93 |
| Average True Range (ATR) | 0.48 | 0.71 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 35.41 | 6.55 |
Price Performance
Historical ComparisonAbout SAFE Safehold Inc. New
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.